The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000572369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
17/04/2026
Date registered
Help: Date registered
7/05/2026
Date last updated
Help: Date last updated
7/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
GAMES 3: Glibenclamide Advantage in Malignant Edema and Stroke 3
Scientific title
A phase 3 double-blind, placebo-controlled, randomised trial of intravenous glibenclamide within 10 hours of stroke onset in patients receiving endovascular thrombectomy for large core ischemic stroke.
Additional trial identifiers [1] 316927 0
MBC2501
Universal Trial Number (UTN)
Trial acronym
GAMES-3
Related trial records

Health condition
Health condition(s) studied:
Acute Ischemic stroke 341346 0
Condition category
Condition code
Stroke 337416 337416 0 0
Ischaemic

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intravenous glibenclamide or placebo (8.65 mg total dose administered as a 3-stage continuous infusion over 72 hours):

Day 1 (Hours 0-24)
Participants will receive a Bolus infusion of glibenclamide or placebo (0.13 mg) over 2 minutes followed by an Infusion of 3.04 mg over 6 hr (at a rate of 11.1mL/hr) the infusion rate is decreased to 7.7mL/hr for 18 hrs.

Day 2 (Hours >24-48)
The participants receive glibenclamide or placebo (2.74 mg) for 24 hrs at a rate of 7.7mL/hr.

Day 3 (Hours >48-72)
The participants receive glibenclamide or placebo (2.74 mg) for 24 hrs at a rate of 7.7mL/hr.

Monitors will visit each site to review pharmacy and medical records to ensure intervention adherence and protocol compliance.
Intervention code [1] 333638 0
Treatment: Drugs
Description of the comparator or control
A placebo will be used as a comparator for this study. The placebo is inactive fluid that looks identical to the glibenclamide infusion containing saline and sterile white lyophilised powder.
Control group
Placebo

Outcomes
Primary outcome [1] 344940 0
Participant functional outcome.
Timepoint [1] 344940 0
3 Months post commencement of intervention.
Secondary outcome [1] 459953 0
Percentage of participants reaching the mRS functional outcome Categories 0-3.
Timepoint [1] 459953 0
3 Months post commencement of intervention.
Secondary outcome [2] 459967 0
Brain Midline Shift.
Timepoint [2] 459967 0
72-96hrs post commencement of intervention.
Secondary outcome [3] 459968 0
Percentage of participants reaching the mRS functional outcome categories 0-2.
Timepoint [3] 459968 0
3 months post commencement of intervention,

Eligibility
Key inclusion criteria
1. Patients presenting with acute ischemic stroke due to anterior circulation large vessel occlusion with ability to randomise and commence the investigational product within 10 hours of the time they were last known to be well, or the midpoint of sleep for wakeup stroke.
2. Patient’s age is 18-80 years (inclusive) at the time of informed consent.
3. National Institutes of Health Stroke Scale (NIHSS) 10-25 (inclusive).
4. Commitment to perform EVT, or EVT is underway or completed.
5. Informed consent or emergency treatment approved by ethics committee as per local requirements.

Imaging inclusion criteria
6. Arterial occlusion on CTA or MRA of the intracranial internal carotid artery (ICA), or first segment (M1) or dominant second segment (M2) of the middle cerebral artery (MCA).
7. Ischemic core 70-125mL on CT-perfusion or diffusion MRI performed not more than 3 hours prior to randomisation.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Brain hemorrhage (other than small petechial/punctate hemorrhages) identified by CT or MRI.
2. Extensive hypodensity on NCCT outside the perfusion lesion that, in the investigator’s opinion, indicates >125mL ischemic core volume.
3. Rapidly improving symptoms that make EVT unlikely to be performed, at the discretion of the investigator.
4. Significant pre-stroke disability: unable to independently perform all duties and activities of daily living without assistance from a caregiver, spouse, or another person.
5. Commitment to immediately perform hemicraniectomy at the time of randomisation.
6. Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the Investigator to be sufficiently serious so as to affect functional outcome. This would include, for example, a contralateral ACA infarct that leads to bilateral leg paralysis.
7. Clinical signs of herniation, e.g., 1 or 2 fixed, dilated pupils; unconsciousness related to edema (i.e., =2 on item 1a on the NIHSS); and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator’s judgment.
8. NCCT/MRI evidence of anteroseptal/pineal shift >2 mm on the baseline imaging, as assessed by the investigator.
9. The participant is likely to have supportive care withdrawn in the first 3 days, in the judgment of the Investigator.
10. Known allergy to glibenclamide or to another sulfonylurea drug or any of the components of the formulated glibenclamide or matching placebo.
11. Patients who are known to have taken oral glibenclamide within the past 10 hours.
12. Known history of clinically significant severe form of renal or hepatic disorder, in the Investigator's opinion (e.g., dialysis or cirrhosis, respectively).
13. Known history of chronic obstructive pulmonary disease that, in the judgment of the Investigator, is severe (e.g., requiring home oxygen).
14. Known history of clinically significant hypoglycemia, in the Investigator's opinion based on known medical history or local screening laboratory assessments (i.e., screening blood glucose <3.9mmol/L (70 mg/dL).
15. Patients who have or have ever had diabetic ketoacidosis or diabetic coma/precoma.
16. Acute ST elevation myocardial infarction (MI), and/or acute decompensated heart failure, and/or admission for an acute coronary syndrome, MI, cardiac arrest, or non-elective coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months.
17. New York Heart Association heart failure III/IV (class III: marked limitation in activity due to symptoms, even during less-thanordinary activity, e.g. walking short distances (20-100 m); class IV: severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients).
18. Patients with known glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency.
19. Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) that required hospitalisation or was clinically significant in the opinion of the Investigator within 3 days prior to Screening.
20. Females who are pregnant or women of childbearing potential with a positive pregnancy test at time of admission.
21. Nursing women who are unable to stop breastfeeding during study treatment infusion and for 7 days following the end of study treatment infusion.
22. Known current participation or known history of participation in any other investigational study that involved treatment with an investigational drug within 14 days prior to enrolment.
23. Any terminal illness such that patient would not be expected to survive more than 1 year.
24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participant Randomisation will be generated by an Interactive Web Response system (IWRS).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Common scale minimum sufficient balance randomisation with group size control will be used to balance each age group (first stratify 18-70 years and >70-80 years) using estimated core volume, NIHSS, age, prior thrombolytic use, wake-up stroke vs. non-wake-up 4.5 hours.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321522 0
Government body
Name [1] 321522 0
National Health and Medical Research Council
Country [1] 321522 0
Australia
Funding source category [2] 321547 0
Commercial sector/Industry
Name [2] 321547 0
Remedy Pharmaceuticals
Country [2] 321547 0
Australia
Primary sponsor type
Other Collaborative groups
Name
The Florey Institute of Neuroscience and Mental Health
Address
Country
Australia
Secondary sponsor category [1] 324288 0
None
Name [1] 324288 0
Address [1] 324288 0
Country [1] 324288 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320056 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 320056 0
Ethics committee country [1] 320056 0
Australia
Date submitted for ethics approval [1] 320056 0
25/09/2025
Approval date [1] 320056 0
04/03/2026
Ethics approval number [1] 320056 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149290 0
Prof Bruce Campbell
Address 149290 0
Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050
Country 149290 0
Australia
Phone 149290 0
+610393427598
Fax 149290 0
Email 149290 0
Contact person for public queries
Name 149291 0
Bruce Campbell
Address 149291 0
Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050
Country 149291 0
Australia
Phone 149291 0
+610393427598
Fax 149291 0
Email 149291 0
Contact person for scientific queries
Name 149292 0
Bruce Campbell
Address 149292 0
Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050
Country 149292 0
Australia
Phone 149292 0
+610393427598
Fax 149292 0
Email 149292 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.